login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CORVUS PHARMACEUTICALS INC (CRVS) Stock News
USA
-
Nasdaq
- NASDAQ:CRVS -
US2210151005
-
Common Stock
8.56
USD
-0.25 (-2.84%)
Last: 12/8/2025, 8:01:41 PM
8.7501
USD
+0.19 (+2.22%)
After Hours:
12/8/2025, 8:01:41 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CRVS Latest News, Press Relases and Analysis
All
Press Releases
16 hours ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
a month ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
a month ago - By: Benzinga
- Mentions:
KURA
SEE
HRMY
FOLD
...
Earnings Scheduled For November 4, 2025
a month ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
a month ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
4 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
a month ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
2 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
2 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
4 months ago - By: The Motley Fool
Corvus (CRVS) Q2 Loss Beats Estimates
4 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results
4 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025
6 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
6 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress
6 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
6 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
7 months ago - By: Yahoo Finance
- Mentions:
TAP
COST
CRK
NRG
US beer slowdown “cyclical” and will ease, Molson Coors CEO says
7 months ago - By: Stocktwits
- Mentions:
VTI
VXF
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased
7 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
7 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
8 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
8 months ago - By: Yahoo Finance
- Mentions:
META
BP
EPD
NVDA
...
Meta Platforms, Inc. (META): Among Stocks That Could 10X Over the Next 2 Years
8 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
9 months ago - By: Stocktwits
- Mentions:
VXF
IBB
AVSC
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger
9 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
9 months ago - By: Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
Please enable JavaScript to continue using this application.